

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT TRIAL AND APPEAL BOARD

ADAMIS PHARMACEUTICALS CORPORATION
Petitioner

v.

BELCHER PHARMACEUTICALS, LLC
Patent Owner

CASE: IPR2019-01021
U.S. PATENT NO. 9,283,197

**JOINT REQUEST TO TREAT SETTLEMENT AND LICENSE
AGREEMENT AS BUSINESS CONFIDENTIAL INFORMATION AND TO
MAINTAIN SAID AGREEMENT SEPARATE FROM THE PUBLIC FILE
PURSUANT TO 35 U.S.C. § 317(b) AND 37 C.F.R. § 42.74(c)**

Pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c), and the Board's authorization of July 26, 2019, Petitioner Adamis Pharmaceuticals Corporation, LLC and Patent Owner Belcher Pharmaceuticals, LLC jointly request to treat as business confidential information the true copy of the Settlement and License Agreement (Confidential Exhibit 1026) between the parties, as referenced in the parties' Joint Motion to Terminate Pursuant to 35 U.S.C. § 317 and 37 C.F.R. § 42.74, filed concurrently herewith.

35 U.S.C. § 317(b) provides that:

At the request of a party to the proceeding, the agreement or understanding shall be treated as business confidential information, shall be kept separate from the file of the involved patents, and shall be made available only to Federal Government agencies on written request, or to any person on a showing of good cause.

Likewise, 37 C.F.R. § 42.74(c) provides that:

A party to a settlement may request that the settlement be treated as business confidential information and be kept separate from the files of an involved patent or application. The request must be filed with the settlement. If a timely request is filed, the settlement shall only be available:

- (1) To a Government agency on written request to the Board; or

(2) To any other person upon written request to the Board to make the settlement agreement available, along with the fee specified in § 42.15(d) and on a showing of good cause.

The present request, which is being filed contemporaneously with the Settlement and License Agreement, is timely and in accordance with the foregoing authority. Therefore, the parties request that the Settlement and License Agreement (Confidential Exhibit 1026) (i) be treated as business confidential information, (ii) be maintained separate from the publicly available file of the involved patent, and (iii) shall be made available only to Federal Government agencies on written request, or to persons showing good cause on written request, pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c).

Dated: July 29, 2019

Respectfully submitted,

/Jason A. Engel/
Jason A. Engel
Reg. No. 51,654
Customer No. 24573
Jason.Engel.PTAB@klgates.com
T: (312) 807-4236
F: (312) 827-8145
K&L Gates LLP
70 W. Madison Street, Suite 3100
Chicago, IL 60602

Counsel for Petitioner

CERTIFICATE OF SERVICE

The undersigned hereby certifies that on July 29, 2019, a true and correct copy of the foregoing **JOINT REQUEST TO TREAT SETTLEMENT AND LICENSE AGREEMENT AS BUSINESS CONFIDENTIAL INFORMATION AND TO MAINTAIN SAID AGREEMENT SEPARATE FROM THE PUBLIC FILE PURSUANT TO 35 U.S.C. § 317(b) AND 37 C.F.R. § 42.74(c)** was served via electronic mail on the following counsel of record for Patent Owner:

Cole Y. Carlson
cole.carlson@gray-robinson.com
Stefan V. Stein
stefan.stein@gray-robinson.com
ptotpa@gray-robinson.com
GrayRobinson, P.A.
401 E. Jackson Street, Suite 2700
Tampa, FL 33602
Telephone: (813) 273-5000

By: /Jason A. Engel/
Jason A. Engel
Reg. No. 51,654
Customer No. 24573
Jason.Engel.PTAB@klgates.com
T: (312) 807-4236
F: (312) 827-8145
K&L Gates LLP
70 W. Madison Street, Suite 3100
Chicago, IL 60602